EpiVax lanza modelos mejorados con IA para la predicción de la inmunogenicidad

ISPRI™Positive

AI Analysis

Summary

EpiVax announced AI-powered enhancements to ISPRI™, its proprietary in silico platform for evaluating immunogenicity risk in biopharmaceuticals. The updated version includes improved artificial intelligence capabilities for predicting drug immunogenicity.

Importance:3/10

Sentiment:

0.30

AI/Machine LearningImmunogenicityPlatform LaunchIn SilicoBiopharmaceutical

Read the original article

Published by PR Newswire Biotech on September 3, 2026 2:06 PM

Read Original